DR. GUS ROSANIA
Dr Gus Rosania is a professor of pharmaceutical sciences at the University of Michigan. He has received many awards for his research work. He is a vocal advocate for recreational legalization. His research at the Rosania lab studies the microscopic transport properties of small drug-like molecules inside cells. Dr. Rosania’s research program combines biological, chemical, and physical analysis methods and tools to develop drugs with enhanced therapeutic indexes and decreased risks of side effects.
Dr. Rosania has been published 78 times for his work in Pharmaceutical Sciences, Drug Biocrystals, Pharmcokinetics, Formulation, Drug Targeting and Drug Delivery. He was awarded the 2018 American Association of Pharmaceutical Scientists Fellow, AAPS
The Rosania lab studies the microscopic transport properties of small drug-like molecules inside cells. Our overarching hypothesis is that a drug’s microscopic distribution within organelles is as important as its macroscopic distribution in organs in determining efficacy and toxicity. We use microscopic imaging instruments to capture the local distribution and dynamics of small molecules inside cells and analyze image data with innovative computational tools and statistical strategies, combining cheminformatics and machine vision to relate the chemical structure of small molecules to their subcellular distribution. We also develop biochemical analysis methods to study the micro distribution and cellular pharmacokinetics of small drug-like molecules. Lastly, we build mathematical models to simulate drug transport and distribution in single cells and higher order cellular organizations, based on biophysical principles governing molecular transport phenomena at the cellular level.
We envision a day when drugs are designed, optimized, and approved based on their site of action, much as drugs today are designed, optimized, and approved based on their molecular mechanism of action.
His research team brings a lot of research and resources to Circa to advance our goals to become a leader in the medical side of the industry.